Clinical trials: Normal Population
Psoriasis
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00678210
- Testing
- CP-690,550
- Where
- 44 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Pfizer
Atopic Dermatitis
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
The purpose of this study is to determine whether OC000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT02002208
- Testing
- OC000459
- Where
- United Kingdom
- Volunteers
- 142 people
- Sponsor
- Atopix Therapeutics, Ltd.
Dermatitis, Atopic, Eczema
A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT04800315
- Testing
- CC-93538
- Where
- 157 sites in United States, Canada and 4 more
- Volunteers
- 221 people
- Sponsor
- Celgene
Arthritis, Rheumatoid
Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects
This exploratory study aims to assess exposure of healthy subjects to systemic challenge with either LPS or GM-CSF. This will be done by measuring inflammatory mediators and cellular activation markers both in circulation and in…
- Trial name
- NCT03306589
- Testing
- Cantharidin, Lipopolysaccharide, Granulocyte-Macrophage Colony-Stimulating Factor
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Plaque Psoriasis, Skin Diseases
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.
- Trial name
- CLEAR-PS (NCT03358290)
- Testing
- JTE-051
- Where
- 16 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Shionogi Inc.
Cancer Colon, Cancer, Liver
Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)
To evaluate the diagnostic performance of blood-based SPOT-MAS test in symptomatic individuals, the investigators sought to launch a prospective multicenter study, named K-ACCELERATE.
- Conditions
- Cancer Colon, Cancer, Liver, Cancer, Lung, Cancer, Breast
- Trial name
- K-ACCELERATE (NCT06391749)
- Where
- Vietnam
- Volunteers
- 1,000 people
- Sponsor
- Gene Solutions
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Distal Subungual Onychomycosis, Fungal Infection
A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail
This study will be a multicenter, international, randomized, vehicle-controlled, parallel-group, double-blinded study. Subjects who are eligible to participate with a confirmed diagnosis of Distal Subungual onychomycosis (DSO) of…
- Conditions
- Distal Subungual Onychomycosis, Fungal Infection, Fungus, Nail
- Trial name
- NCT04188574
- Testing
- BB2603-1, BB2603-3, BB2603-10
- Where
- 20 sites in Czechia, Germany and 1 more
- Volunteers
- 111 people
- Sponsor
- Blueberry Therapeutics
Atopic Dermatitis, Plaque Psoriasis
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.
- Trial name
- EMPORIA (NCT04664153)
- Testing
- PF-07038124 ointment, Vehicle ointment
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 104 people
- Sponsor
- Pfizer
Long QT Syndrome
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of eleclazine and its metabolite, GS-623134, in participants with normal and impaired renal function.
- Trial name
- NCT02441829
- Testing
- Eleclazine
- Where
- 7 sites in United States, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Uterine Fibroids
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
The purpose of this study is to evaluate the efficacy of Relugolix (TAK-385) 40 mg administered orally once daily for 12 weeks, compared with leuprorelin injection (once every 4 weeks, 1.88 mg or 3.75 mg subcutaneously [SC]/time)…
- Trial name
- NCT02655237
- Testing
- Relugolix, Leuprorelin
- Where
- 25 sites in Japan
- Volunteers
- 281 people
- Sponsor
- Takeda
Systemic Lupus Erythematosus
A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus
It is thought that Edratide may be able to reduce the symptoms of SLE.
- Trial name
- PRELUDE (NCT00203151)
- Testing
- edratide
- Volunteers
- 340 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Severe Hepatic Impairment
Evaluate Severe Hepatic Impairment on Dacomitinib PK
This is a post approval requirement to study the effect of severe hepatic impairment on the pharmacokinetics of dacomitinib.
- Trial name
- NCT03865446
- Testing
- Dacomitinib
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Human Immunodeficiency Virus (HIV) Infection
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
The purpose of this study is to assess whether a dosing adjustment is needed in patients with renal impairment.
- Trial name
- NCT00717067
- Testing
- Maraviroc, Ritonavir, Saquinavir
- Where
- 2 sites in Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Vitiligo, Depressive Episode
Mental Health Associations With Vitiligo
This cohort study is a large population-based study in the UK to determine the risks of comorbid mental health conditions (including depression, anxiety and other potential psychological complications of vitiligo) in adults with…
- Conditions
- Vitiligo, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04953338
- Testing
- Exposure of mental health condtion of interest
- Where
- United Kingdom
- Volunteers
- 36,104 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Breast Cancer
Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients
The primary purpose of this study is to establish if a 10.8 mg dose of ZOLADEX given 3 monthly is non-inferior to a 3.6 mg dose of ZOLADEX given monthly in terms of oestradiol suppression in patients with oestrogen receptor…
- Trial name
- NCT00303524
- Testing
- Goserelin acetate
- Where
- 22 sites in Japan
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Cutaneous Neurofibroma, Neurofibromatosis 1
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
This is a randomized, double-blind, vehicle-controlled, parallel group dose response study evaluating the safety and effectiveness of 2 concentrations of NFX-179 gel in participants with cNF.
- Trial name
- NCT05005845
- Testing
- NFX-179 gel, Vehicle gel
- Where
- 23 sites in United States
- Volunteers
- 199 people
- Sponsor
- NFlection Therapeutics, Inc.
Moderate-to-Severe Atopic Dermatitis
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study was to assess the pharmacokinetics (PK), safety, and efficacy of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04921345
- Testing
- Nemolizumab
- Where
- 23 sites in United States, Denmark and 3 more
- Volunteers
- 109 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and…
- Trial name
- NCT04668066
- Testing
- PF-07242813
- Where
- 7 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Pfizer
Acne Vulgaris
Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
To evaluate the therapeutic effect of DPSG and Placebo gel in the treatment of acne vulgaris.
- Trial name
- NCT03132194
- Testing
- DPSG 7.5%, Aczone
- Volunteers
- 1,125 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.